Share of insuline glargine sales Lantus vs. biosimilar US 2015-2017

This statistic depicts the share of insulin glargine sales attributable to Lantus compared to its biosimilar from 2015 to 2017. In 2015, Lantus held 100 percent of the insulin glargine sales in the United States. However, as of November 2017, Lantus held 81.1 percent of the market while biosimilar Basaglar held 18.9 percent of the market.

Insulin glargine market share of Lantus and its U.S. biosimilar competitor from 2015 to 2017

Lantus (originator)Basaglar (biosimilar)
Exclusive Premium statistic

You need a Premium Account for unlimited access.

  • Full access to 1m statistics

  • Incl. source references

  • Available to download in PNG, PDF, XLS format

Premium Account

only $59 / month *
*Duration: 12 months, billed annually, single license

Access to this and all other statistics on 80,000 topics from

$708 / Year

Show detailed source information?
Register for free
Already a member?
Log in

Release date

February 2018


United States

Survey time period

2015 to 2017

Supplementary notes

* Year to date November 2017.

Statista Accounts: Access All Statistics. Starting from $708 / Year
Basic Account
Get to know the platform

You only have access to basic statistics.
This statistic is not included in your account!

Premium Account
Your perfect start with Statista
  • Instant access to 1m statistics
  • Download in XLS, PDF & PNG format
  • Detailed references

$59 / Month *

Corporate Account
Full access

Corporate solution including all features.

* All products require an annual contract.
   Prices do not include sales tax.

Statistics on "Generics and biosimilars"

Statista Accounts: Access All Statistics. Starting from $708 / Year
Learn more about how Statista can support your business.